SIETES :: 93212 citas

Resultados de la búsqueda por ALUCINACIONES REFINAR BÚSQUEDA

1.

Webster P. Pimavanserin evaluated by the FDA. Lancet 2018;391:5 de mayo. [Ref.ID 102594]

2.

Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic pot: not your grandfathers marijuana. Trends Pharmacol Sci 2017;38:257-76. [Ref.ID 101989]

3.

Patel AN, Lee S, Andrews HF, Pelton GH, Schultz SK, Sultzer DL, Mintzer J, de la Pena D, Gupta S, Colon S, Schimming C, Levin B, Devanand DP. Prediction of relapse after discontinuation of antipsychotic treatment in Alzheimer’s disease: the role of hallucinations. Am J Psychiatry 2016:. [Ref.ID 100993]

4.

Anónimo. FDA fast tracks approval of treatment for hallucinations in patients with Parkinson’s disease . DIA Daily 2016:3. [Ref.ID 100924]

5.

Anónimo. Pimavanserin (Nuplazid) for Parkinson's disease psychosis. Med Lett Drugs Ther 2016;58:74-5. [Ref.ID 100456]

6.

Anónimo. FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease. U.S. Food and Drug Administration 2016:29 de abril. [Ref.ID 100215]

7.

Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid - Related illnesses and deahts. N Engl J Med 2015;373:103-7. [Ref.ID 99338]

8.

Anónimo. Suvorexant (Belsomra) for insomnia. Med Lett Drugs Ther 2015;57:29-31. [Ref.ID 98878]

9.

Anónimo. Gabapentine et prégabaline: une toxicité hépatique et sanguine parfois grave. Prescrire 2014;34:515-6. [Ref.ID 98076]

10.

Pellegrino P, Carnovale C, Borsadoli C, Danini T, Speziali A, Perrone V, Antoniazzi S, Pozzi M, Clementi E, Radice S. Two cases of hallucination in elderly patients due to a probable interaction between flu immunization and tramadol. Eur J Clin Pharmacol 2013;69:1615-6. [Ref.ID 95991]

11.

Anónimo. Duloxétine: syndromes de sevrage. Prescrire 2013;33:517. [Ref.ID 95944]

12.

Anónimo. Pour mieux soigner: des médicaments à écarter. Prescrire 2013;33:138-42. [Ref.ID 94882]

13.

Anónimo. Ranolazine: hallucinations. Prescrire 2012;32:917. [Ref.ID 94200]

14.

Anónimo. Zolpidem. Continued reporting of abnormal sleep-related events and amnesia. WHO Pharmaceuticals Newsletter 2012;4:12-3. [Ref.ID 93681]

15.

Anónimo. Rasagiline (Azilect) for Parkinson’s disease. Another option for the individualised treatment of Parkinson's disease. NPS Radar 2012:8 de agosto. [Ref.ID 92896]

16.

Anónimo. Zolpidem: continued reporting of abnormal sleep-related events and amnesia. Australian Prescriber 2012;35:99. [Ref.ID 92636]

17.

Anónimo. Ranolazine and hallucination. WHO Pharmaceuticals Newsletter 2012;2:abril. [Ref.ID 92616]

18.

Garjón Parra J. ¿Y si fuera el medicamento? Síntomas comunes que pueden deberse a reacciones adversas. Boletín de Información Farmacoterapéutica de Navarra 2011;19:17-27. [Ref.ID 91190]

19.

Anónimo. Benzonatate warning. Med Lett Drugs Ther 2011;53:9. [Ref.ID 90163]

20.

Vitalone A, Menniti-Ippolito F, Moro PA, Firenzuoli F, Raschetti R, Mazzanti G. Suspected adverse reactions associated with herbal products used for weight loss: a case series reported to the Italian National Institute of Health. Eur J Clin Pharmacol 2011;67:215-24. [Ref.ID 90094]